原发性胆汁性胆管炎药物评估与监管审批:路在何方
原发性胆汁性胆管炎(PBC)是一种慢性胆汁淤积性肝病,熊去氧胆酸治疗后仍有高达40%的患者应答不充分,存在进展至肝硬化的风险。奥贝胆酸作为二线治疗改善了部分患者结局,但基于生化标志物的条件性上市许可要求后续确证性随机安慰剂对照结局试验,COBALT研究显示当已有 licensed 药物可及性时难以保留患者。本文探讨欧洲药品管理局(EMA)反思文件对PBC治疗的影响,并提出通过真实世界数据收集长期结局证据的实用解决方案。
要点
- 高达40%的PBC患者对熊去氧胆酸应答不充分,仍面临疾病进展至肝硬化的风险。
- 奥贝胆酸作为二线治疗改善了熊去氧胆酸治疗失败患者的结局,但高风险患者仍需更好的治疗。
- 基于生化标志物的条件性上市许可要求后续确证性随机安慰剂对照结局试验,但COBALT研究显示当已有 licensed 药物可及性时难以保留患者。
核心结论
- PBC治疗改善的最大威胁是条件性上市许可监管模式,该模式基于生化标志物批准新药并要求长期随机安慰剂对照结局试验确证疗效。
- COBALT确证研究显示,当已有 licensed 药物可及性时,难以在所需的后续确证性安慰剂对照PBC结局试验中保留患者。
- EMA反思文件未认识到真实世界数据在提供罕见病结局获益证据中的重要性,作者提出通过真实世界数据收集长期结局证据的实用解决方案。
研究设计与样本
- 本文为综述类文章,探讨PBC药物评估与监管审批路径,并分析EMA反思文件对PBC治疗的影响。
主要发现
- 高达40%的PBC患者对熊去氧胆酸应答不充分,仍存在进展至肝硬化的风险。
- 奥贝胆酸作为二线治疗改善了熊去氧胆酸治疗失败患者的结局,但高风险患者仍需更好的治疗。
- COBALT确证研究显示,当已有 licensed 药物可及性时,难以在所需的后续确证性安慰剂对照PBC结局试验中保留患者。
- 正在开发的新PBC疗法(如过氧化物酶体增殖物激活受体激动剂)在条件性上市许可后,通过随机安慰剂对照研究证明结局获益面临更大挑战,因为将有更多治疗选择可用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. The management landscape was transformed 20 years ago with the advent of ursodeoxycholic acid. Up to 40% of patients do not, however, respond adequately to ursodeoxycholic acid and therefore still remain at risk of disease progression to cirrhosis. The introduction of obeticholic acid as a second-line therapy for patients failing ursodeoxycholic acid has improved outcomes for patients with PBC. There remains, however, a need for better treatment for patients at higher risk. The greatest threat facing our efforts to improve treatment in PBC is, paradoxically, the regulatory approval model providing conditional marketing authorization for new drugs based on biochemical markers on the condition that long-term, randomized placebo-controlled outcome trials are performed to confirm efficacy. As demonstrated by the COBALT confirmatory study with obeticholic acid, it is difficult to retain patients in the required follow-on confirmatory placebo-controlled PBC outcome trials when a licensed drug is commercially available. New PBC therapies in development, such as the peroxisome proliferator-activated receptor agonists, face even greater challenges in demonstrating outcome benefit through randomized placebo-controlled studies once following conditional marketing authorization, as there will be even more treatment options available. A recently published EMA Reflection Paper provides some guidance on the regulatory pathway to full approval but fails to recognize the importance of real-world data in providing evidence of outcome benefit in rare diseases. Here we explore the impact of the EMA reflection paper on PBC therapy and offer pragmatic solutions for generating evidence of long-term outcomes through real-world data collection.
引用
- Jones DEJ, Beuers U, Bonder A, et al. Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here? Hepatology. 2024. PMID: 38506926. doi:10.1097/HEP.0000000000000864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。